USING MALDI-TOF TO CHARACTERIZE NEW BIOMARKERS THAT PREDICT DOWN'S SYNDROME

Researchers at Middlesex University, UK, are using a Shimadzu MALDI-TOF mass spectrometer to analyze the association of hyperglycosylated human chorionic gonadotrophin (hCG) hormone with diseases.

A heavily glycosylated fragment of hCG has been shown to be produced by malignant tumors and has been observed during abnormal pregnancies, such as Down's syndrome.

"The Shimadzu MALDI-TOF's high resolution range means we can look at our higher mass molecules - around 10-50 kDa - without having to modify them first, and this is a huge advantage," explained Prof Ray Iles, Associate Dean of Research at the School of Health and Social Sciences.

"The hCG hormone and a metabolite, hCGb, are present in urine in relatively large amounts so it is easy to obtain samples from patients and analyse the molecule's degree of hyperglycosylation. Our preliminary work has shown that the molecules have different glycosylation patterns for various diseases and we are now running thousands of urine samples through the MALDI-TOF system to look at the spectral patterns.

We hope to find specific structural alterations of the hCG molecules associated with certain conditions, such as Down's syndrome pregnancies, as this could provide a revolutionary diagnostic test that would be very quick, easy and cheap to perform."

Prof Iles' department has a fleet of mass spectrometers from Shimadzu for a wide range of projects. "I was looking for instruments that would be consistent for anyone within the department to use, from water quality studies to herbal medicine analyses," he said.

"The Shimadzu software is very intuitive, so people trained on one spectrometer can easily move on to the next. Another advantage is the service contract and back up, Shimadzu supports us fantastically well and no other company can beat it!"

Further Information: http://www.mdx.ac.uk/hssc/research/centres/biomed/bio.asp

-ends-

About Shimadzu Biotech

Shimadzu Biotech is a strategic global brand of Shimadzu Corporation. Shimadzu Biotech is focused on providing integrated solutions for life science and drug development to accelerate the progress of biotechnology in research and development. Shimadzu Biotech represents a new way of thinking in the health and life science sectors by combining a core competence in instrument design and manufacture together with strategic partnerships to advance the development of knowledge in biotechnology. Product offerings include mass spectrometry integrated with enabling technology for high throughput analysis (MALDI, LC/MS, automated systems for analyzing gels with mass spectrometry) and specific solutions for DNA analysis (ranging from UV spectroscopy to chip-based electrophoresis) among a range of other offerings.

For more information, please contact:

Shimadzu Biotech

For press information, please contact: